UNSPSC 51144129: Lisdexamfetamine mesilate or mesylate

This classification denotes a cns stimulant and anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SJT761GEGS. European Medicines Agency schedules Lisdexamfetamine dimesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32146. Lisdexamfetamine mesilate generally arises in the molecular formula C15H25N3O.2CH4O3S. The term 'lisdexamfetamine mesilate' is a U.S. FDA Orange Book designation.

Most nations, for tariff and trade purposes, schedule lisdexamfetamine mesilate under HS 29242990 and SITC 51479. SMILES: C[C@@H](CC1CCCCC1)NC(=O)[C@H](CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O.

UNSPSC 51144129 Lisdexamfetamine mesilate or mesylate is a Commodity code that in recent state and local procurement activity covers the sourcing of pharmaceutical products, including controlled substances and OTC items, through competitive bidding and cooperative purchasing vehicles. State and local health agencies, county governments, and multistate purchasing alliances are the primary issuing bodies, with procurement spanning naloxone procurement for community health initiatives, direct-to-manufacturer prescription program development, and generic pharmaceutical supply agreements. The scope includes detailed product specification and supply chain compliance requirements, such as National Drug Code (NDC) tracking, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA clearance, along with contractual relationships with authorized pharmaceutical wholesalers and quarterly or ongoing delivery schedules.

Recent activity shows solicitation across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct relationships between the state's pharmacy benefit program and manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026, and pricing evaluation weighted 75 percent on price competitiveness. Vendors across these solicitations must comply with E-Verify requirements, maintain specific insurance coverages, and adhere to federal compliance standards including the Clean Air Act and Federal Water Pollution Control Act where FEMA funding is involved.